Quick summary
Thymopoietin is a 49-amino acid thymic hormone that drives T-lymphocyte differentiation and maturation. It is the parent protein of the clinically active pentapeptide Thymopentin (TP-5) and serves as a historical benchmark in thymic peptide immunology research.
Overview
Thymopoietin is a 49-amino acid thymic hormone produced by thymic epithelial cells, existing as isoforms (Thymopoietin I, II, and III). It plays a central role in T-lymphocyte differentiation and maturation, helping to establish and maintain cell-mediated immunity. Research has focused on its immunomodulatory properties in aging, immunodeficiency states, and as the parent protein from which the active pentapeptide Thymopentin (TP-5) was derived.
Mechanism of action
Thymopoietin acts on lymphoid progenitor cells to induce T-cell lineage commitment and differentiation markers. It suppresses neuromuscular transmission (early research linked it to myasthenia gravis) via acetylcholine receptor modulation. Its immunological actions are mediated through the active pentapeptide sequence (residues 32–36, Arg-Lys-Asp-Val-Tyr), which corresponds to Thymopentin. Full-length Thymopoietin is thought to interact with both immune cell receptors and nuclear lamina proteins in its role as a structural component.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| immunological research | subcutaneous | 1–10 mg | per experimental protocol |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Thymopoietin research established the concept of thymic hormonal control of T-cell development. Early studies in the 1970s–1980s by Gideon Goldstein's group characterized its structure and immunological activity. Later research led to isolation of the active TP-5 fragment. Interest has extended to Thymopoietin's role as a nuclear lamina protein (LAP2), with implications for progeria-like diseases and DNA repair. Modern immunotherapy research treats Thymopoietin as a historical benchmark for thymic peptide pharmacology.[1][2][3][4]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Thymopoietin for synergistic effects.
Legal status
Thymopoietin (full-length 49 AA) is not approved for human use and is classified as a research compound. Its active fragment Thymopentin (TP-5) has been approved in some countries.
Sourcing & access
Research compound
Thymopoietin is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Thymopoietin is a 49-amino acid hormone produced by thymic epithelial cells that plays a central role in T-cell differentiation and maturation. It exists as multiple isoforms and is the parent protein from which the active pentapeptide Thymopentin (TP-5) was derived.
Thymopoietin acts on lymphoid progenitor cells to induce T-cell lineage commitment and differentiation markers. Its immunological actions are mediated through the active pentapeptide sequence at residues 32-36 (Arg-Lys-Asp-Val-Tyr). It also modulates acetylcholine receptor signaling and functions as a nuclear lamina protein.
Reported side effects in research settings include injection site reactions and transient immune activation. Full-length Thymopoietin is classified as research-only and is not approved for human clinical use, though its active fragment Thymopentin has been approved in some countries.
Thymopentin (TP-5) is the synthetic pentapeptide corresponding to residues 32-36 of Thymopoietin. This five-amino acid fragment retains the full immunomodulatory activity of the parent protein and has been developed as a clinical immunomodulator approved in Italy and other countries.
Research references
- Thymopoietin: a thymic hormone regulating T-cell differentiationPubMed
- Thymopoietin receptor signaling and T-lymphocyte maturationPubMed
- Clinical applications of thymopoietin and its pentapeptide fragment thymopentinPubMed
- Thymopoietin II and antigen-independent induction of T-cell differentiation markersPubMed